Inspired by patients. Driven by science.
UCB – Inspired by patients. Driven by science. At UCB, we put our heart, soul and skills into making a difference for people living with severe diseases. We look to transform patients’ lives by pushing the boundaries of what is possible. With us, our talents makes the most of who they are, unlocking innovation and setting new standards for patients.
Everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?”
And to find the answers, we connect globally with patients and their families living with the physical and social burdens of severe disease. These connections give us new perspectives, drive our innovation, and offer a hope for a new generation of therapies that will help to transform lives.
UCB – The Facts
With approximately 9000 employees in around 40 countries, we are a global biopharmaceutical company headquartered in Brussels, Belgium which invests more than 25% of revenue in cutting-edge scientific research to meet unmet patient needs.
A few other reasons that make UCB an amazing place to work:
- Promising pipeline that includes several novel molecules;
- 2023 Key Financials: € 5.3 billion global revenue
Specialties: Neurology, Immunology
Neurology, Immunology, and Healthcare Innovation Beyond Medicine
Home | UCB
Entity | Type | Tweets | Articles | |
---|---|---|---|---|
Duke University School of Medicine Higher Education | Other 23 Oct 2018 | | ||
Icahn School of Medicine at Mount Sinai healthtech, Hospitals and Health Care | Other 13 Dec 2018 | | ||
Interpat legaltech, Government Administration | Other 26 Apr 2021 | | ||
PhRMA biotech, deeptech, Pharmaceutical Manufacturing | Other 10 May 2023 | | ||
MedInTechs Events Services, healthtech | Other 9 Mar 2022 | | ||
Johns Hopkins Technology Ventures (JHTV) Research Services | Other 12 Jun 2019 | | ||
Truveta healthtech, Hospitals and Health Care | Other 31 Oct 2023 | | ||
Alliance maladies rares healthtech, Non-profit Organizations | Other 2 Jun 2024 | | ||
Duke Capital Partners Venture Capital and Private Equity Principals | Other 2 Oct 2018 | | ||
Tufts Center for the Study of Drug Development deeptech, Pharmaceutical Manufacturing | Other 9 Aug 2022 | |